8:25-cr-00070•USA v. Perdomo et al
Testo completo
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEBRASKA UNITED STATES OF AMERICA, Plaintiff, vs. EDUARDO JOSE PERDOMO, MICHEL MARTINEZ-GONZALEZ, ALFREDO ZAMBRANO-HURTADO, SUMIT CHAUDHARI, KAVANKUMAR PATEL, and VISHAL GOSWAMI, Defendants. 8:25CR70 ORDER This matter is before the Court on defendant Eduardo Jose Perdomo’s Unopposed Motion to Continue Trial (Filing No. 98). Counsel continues to receive discovery and needs additional time to review discovery and to reach a negotiation. The government and counsel for all co- defendants have no objection to the continuance. For good cause shown, IT IS ORDERED that the Motion to Continue Trial [98] is granted, as follows: 1. The jury trial, for all defendants, now set for December 15, 2025, is continued to March 2, 2026. 2. In accordance with 18 U.S.C. § 3161(h)(7)(A), the court finds that the ends of justice will be served by granting this continuance and outweigh the interests of the public and the defendants in a speedy trial. Any additional time arising as a result of the granting of this motion, that is, the time between today’s date and March 2, 2026, shall be deemed excludable time in any computation of time under the requirement of the Speedy Trial Act. Failure to grant a continuance would deny counsel the reasonable time necessary for effective preparation, taking into account the exercise of due diligence. 18 U.S.C. § 3161(h)(6), (7)(A) & (B)(iv). 3. No further continuances will be granted barring exceptional circumstances. Dated this 26th day of November, 2025. BY THE COURT: s/ Joseph F. Bataillon Senior United States District Judge 8:25-cr-00070-JFB-MDN Doc # 99 Filed: 11/26/25 Page 1 of 1 - Page ID # <pageID>
Ti chiedi come si applica questo testo alla tua situazione?
Consulenza gratuita, senza impegno
Descrivi la tua situazione. Il nostro team ti ricontatterà via e-mail per la tua consulenza.
Continua la tua ricerca in ChatGPT o Claude
Collega Omnilex per cercare nel corpus legale dal tuo assistente IA.